|
1）Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015; 56: 45-9
|
|
|
|
2）Kwon W, Howard BA, Herndon JE, et al. FDG uptake on positron emission tomography correlates with survival and time to recurrence in patients with stage I non-small-cell lung cancer.J Thorac Oncol. 2015; 10: 897-902
|
|
|
|
|
|
3）Huang W, Liu B, Fan M, et al. The early predictive value of a decrease of metabolic tumor volume in repeated 18F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy. Eur J Radiol. 2015; 84: 482-8
|
|
|
|
|
|
4）LoGiurato B, Matthews R, Safaie E, et al. 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer. Nucl Med Commun. 2015 May 11. [Epub ahead of print]
|
|
|
|
|
|
5）Marcus C, Paidpally V, Antoniou A, et al. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. J Nucl Med. 2015; 56: 204-8
|
|
|
|
|
|
6）Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline （version 1.1）. Eur J Cancer. 2009; 45: 228-47
|
|
|
|
|
|
7）Lee HY, Lee KS, Ahn MJ, et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 2011; 73: 63-9
|
|
|
|
|
|
8）Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009 ; 50 Suppl 1: 122S-50S
|
|
|
|
|
|
9）Ding Q, Cheng X, Yang L, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors （PERCIST） versus response evaluation criteria in solid tumors （RECIST）. J Thorac Dis. 2014; 6: 677-83
|
|
|
|
|
|
10）Ziai D, Wagner T, El Badaoui A, et al. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging. 2013; 13: 73-80
|
|
|
|
|
|
11）Kanazu M, Maruyama K, Ando M, et al. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction. Clin Lung Cancer. 2014; 15: 182-7
|
|
|
|
|
|
12）Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008; 59: 203-10
|
|
|
|
|
|
13）Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009; 50 Suppl 1: 31S-42S
|
|
|
|
|
|
14）磯部和順，秦 美暢，杉本圭史，他．間質性肺炎合併肺癌の診断におけるFDG-PETの有用性の検討．日呼吸会誌．2009; 47: 278-85
|
|
|
|
|
|
15）Furukawa M, Oto T, Yamane M, et al. Spontaneous regression of primary lung cancer arising from an emphysematous bulla. Ann Thorac Cardiovasc Surg. 2011; 17: 577-9
|
|
|
|
|
16）Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002; 43: 876-81
|
|
|
|
|
|
17）Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004; 45: 1287-92
|
|
|
|
|
|
18）Lupi A, Zaroccolo M, Salgarello M, et al. The effect of 18F-FDG-PET/CT respiratory gating on detected metabolic activity in lung lesions. Ann Nucl Med. 2009; 23: 191-6
|
|
|
|
|
|
19）Otani T, Otsuka H, Kondo K, et al. Utility of respiratory-gated small-animal PET/CT in the chronologic evaluation of an orthotopic lung cancer transplantation mouse model. Radiol Phys Technol. 2015 Apr 29. [Epub ahead of print]
|
|
|
|
|
|
20）Torizuka T, Tanizaki Y, Kanno T, et al. Single 20-second acquisition of deep-inspiration breath-hold PET/CT: clinical feasibility for lung cancer. J Nucl Med. 2009; 50: 1579-84
|
|
|
|
|
|
21）Kawano T1, Ohtake E, Inoue T. Deep-inspiration breath-hold PET/CT of lung cancer: maximum standardized uptake value analysis of 108 patients. J Nucl Med. 2008; 49: 1223-31
|
|
|
|
|
|
22）Würslin C, Schmidt H, Martirosian P, et al. Respiratory motion correction in oncologic PET using T1-weighted MR imaging on a simultaneous whole-body PET/MR system. J Nucl Med. 2013; 54: 464-71
|
|
|
|
|
|
23）日本核医学会，日本医学放射線学会，日本磁気共鳴医学会．FDG PET/MRI診療ガイドライン 2012 Ver 1.0. 2012
|
|
|
|
|
|
24）Fan L, Sher A, Kohan A, et al. PET/MRI in lung cancer. Semin Roentgenol. 2014; 49: 291-303
|
|
|
|
|
|
25）Yoon SH, Goo JM, Lee SM, et al. Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: current status and future prospects. J Thorac Imaging. 2014; 29: 4-16
|
|
|
|
|
|
26）Heusch P, Buchbender C, Köhler J, et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014; 55: 373-8
|
|
|
|
|
|
27）Sachpekidis C, Thieke C, Askoxylakis V, et al. Combined use of 18F-FDG and 18F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging. 2015; 5: 127-42
|
|
|
|
|
|
28）Hoyng LL, Frings V, Hoekstra OS, et al. Metabolically active tumour volume segmentation from dynamic [18F]FLT PET studies in non-small cell lung cancer. EJNMMI Res. 2015; 5: 26
|
|
|
|
|
|
29）Kaira K, Oriuchi N, Shimizu K, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 2010; 37: 911-6
|
|
|
|
|